NMT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1848864	1.00	20/20
Zelenirstat (SCHEMBL1849576)	1.00	20/20
SCHEMBL1852194	1.00	20/20
SCHEMBL1852254	1.00	20/20
SCHEMBL1852481	1.00	20/20
SCHEMBL1852723	1.00	20/20
SCHEMBL1853435	1.00	20/20
SCHEMBL1853857	1.00	20/20
SCHEMBL1853897	1.00	20/20
SCHEMBL1854672	1.00	20/20
SCHEMBL1855598	1.00	20/20
Hydrochloric Acid (SCHEMBL1851417)	0.98	20/20
Hydrochloric Acid (SCHEMBL1848915)	0.98	20/20
SCHEMBL1855557	0.77	20/20
SCHEMBL1854733	0.72	20/20
SCHEMBL1848819	0.70	20/20
SCHEMBL1851188	0.66	20/20
Hydrochloric Acid (SCHEMBL1855461)	0.65	20/20
SCHEMBL1853540	0.64	20/20
SCHEMBL1849802	1.00	19/20

Clinical trials — most relevant to NMT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine	PHASE2	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC	nan	COMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
NGLY1 Natural History	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)	nan	RECRUITING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery	nan	NOT_YET_RECRUITING
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients	nan	UNKNOWN
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
Markers and Mechanisms of Macrovascular Disease in IDDM	nan	COMPLETED
Identification and Characterization of Monogenic Diabetes	nan	COMPLETED
Chest Wall Deformities in Children - Epidemiological Data	nan	COMPLETED
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)	nan	RECRUITING
External Nitric Oxide Measurement Through SNO Degradation	nan	ENROLLING_BY_INVITATION
Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan	nan	ENROLLING_BY_INVITATION
Human Requirements for the Nutrient Choline	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NMT1 binder may also engage these)

Protein	Name	Similarity
P31717	—	1.000	P31717 →
O70310	—	1.000	O70310 →
NMT2	Glycylpeptide N-tetradecanoyltransferase 2	1.000	landscape →
Q5RAF3	—	1.000	Q5RAF3 →
Q8K1Q0	—	0.997	Q8K1Q0 →
Q9N181	—	0.995	Q9N181 →
A7YT82	—	0.994	A7YT82 →
O70311	—	0.988	O70311 →
O61613	—	0.985	O61613 →
Q9LTR9	—	0.985	Q9LTR9 →
Q75EK2	—	0.985	Q75EK2 →
Q8N1G2	—	0.985	Q8N1G2 →
Q5R981	—	0.983	Q5R981 →
P46548	—	0.983	P46548 →
Q9DBC3	—	0.982	Q9DBC3 →
Q99LC3	—	0.981	Q99LC3 →
NAT10	RNA cytidine acetyltransferase	0.980	landscape →
Q8IYB8	—	0.980	Q8IYB8 →
P31266	—	0.979	P31266 →
P0CP20	—	0.979	P0CP20 →
B3M1E1	—	0.979	B3M1E1 →
P34809	—	0.979	P34809 →
LIG3	DNA ligase 3	0.978	landscape →
O00423	—	0.978	O00423 →
P0CP21	—	0.978	P0CP21 →
Q803R5	—	0.978	Q803R5 →
Q95K79	—	0.978	Q95K79 →
Q7T0W1	—	0.978	Q7T0W1 →
P0CB90	—	0.978	P0CB90 →
Q8CE96	—	0.978	Q8CE96 →